TABLE 5.

Results according to eras of LT recipients converted from CNI to MMF-MT.

	First Era (1999–2011) (n = 161)	Second Era (2012–2023) (n = 163)	P
Age (yr)	54 (22–70)	56 (19–70)
Sex (M/F)	111(68.9%)/50 (31.1%)	131 (80.4%)/32 (19.6%)	0.018
Hypertension	33 (20.5%)	17 (10.4%)	0.019
Diabetes mellitus	32 (19.9%)	47 (28.8%)	0.023
MELD Score	15 (7–23)	15 (6–35)
LT indications
Alcoholic cirrhosis	67 (41.6%)	83 (50.9%)	0.093
Hepatitis C virus cirrhosis	63 (39.1%)	70 (42.9%)	0.485
Hepatocellular carcinoma	24 (14.9%)	57 (35.4%)	<0.001
Hepatitis virus B cirrhosis	24 (15%)	19 (11.7%)	0.388
Steatosis  No  Microsteatosis  Macrosteatosis  N/A	24 (14.9%) 42 (26.1%) 71 (44.1%) 24 (14.9%)	37 (22.7%) 33 (20.2%) 67 (41.1%) 26 (15.9%)	0.062
Indications of conversion from CNI to MMF-MT  CKD alone  CKD + Hypertension  CKD + Hypertension + Diabetes mellitus  CKD + Diabetes mellitus  Diabetes mellitus  Hypertension  Recurrent biliary infection	42 (26.1%) 18 (11.2%) 30 (18.6%) 10 (6.2%) 26 (16.1%) 31 (19.2%) 4 (2.5%)	46 (28.2%) 37 (22.7%) 16 (9.8%) 16 (9.8%) 35 (21.5%) 11 (6.7%) 2 (1.2%)	<0.001
Post-MMF-MT acute rejection  Diagnosis by liver biopsy   Grade I   Grade II   Grade III  Diagnosis by liver dysfunction	11 (6.8%) 6 (3.7%) 3 (1.8%) 2 (1.2%) 1 (0.6%) 5 (3.1%)	13 (7.9%) 8 (4.9%) 5 (3.1%) 3 (1.8%) 0 (0%) 5 (3.1%)	0.694
Adverse effects  Diarrhea  Vomiting  Leukopenia  Anemia  Asthenia	26 (16.1%) 7 (4.3%) 4 (2.5%) 13 (8.1%) 1 (0.6%) 1 (0.6%)	22 (13.5%) 11 (6.7%) 2 (1.2%) 6 (3.7%) 2 (1.2%) 1 (0.6%)	0.667
Causes of MMF-MT withdrawal  De novo tumors  Rejection  Liver dysfunction (no liver biopsy)  Liver retransplantation  Kidney transplantation  Adverse effects   • Diarrhea   • Leukopenia	26 (16.1%) 11 (6.7%) 4 (2.5%) 3 (1.9%) 2 (1.2%) 2 (1.2%) 4 (2.5%) 3 (1.9%) 1 (0.6%)	16 (9.8%) 2 (1.2%) 4 (2.4%) 3 (1.8%) 2 (1.2%) 1 (0.6%) 4 (2.4%) 1 (0.6%) 3 (1.8%)	0.460
Actuarial patient survival after MMF-MT  1-y  3-y  5-y  10-y	93.8% 82.3% 70.1% 51.9%	97.9% 91.8% 80.9% 64.3%	0.089